Mitoconix Bio, an innovative Israeli startup bred by Israel’s only life science incubator, FutuRx, has recently raised $20 million to develop a promising drug for the treatment of Huntington’s disease and other neurodegenerative disorders, as reported by the Times of Israel.
Both Mitoconix Bio and FutuRx are clients of GT’s Barry Schindler, co-chair of Greenberg Traurig’s Global Patent Prosecution Group, and an active member of the firm’s Israel Practice. In addition, Elysa Goldberg and Sarah Fashena work closely with both clients.